B
Blueberry Therapeutics
Topical nanomedicines for treating dermatological conditions
About Blueberry Therapeutics
Blueberry Therapeutics is a drug discovery and development company founded in 2011 by Michael John Davies and headquartered in Alderley Edge, United Kingdom. The company concentrates on creating topical nanomedicines for dermatological conditions, particularly infectious and inflammatory diseases of the skin and nail. Its primary business model involves using a proprietary nanopolymer drug delivery system, called Nanocin™, to enhance the delivery of existing drugs into the skin and nails. This approach aims to improve efficacy and safety, allowing for lower doses and shorter treatment durations compared to existing oral or topical treatments.
The company's lead product candidate, BB2603, is a topical nano-formulation of the antifungal drug terbinafine, delivered as a spray to treat onychomycosis (fungal nail infection) and tinea pedis (athlete's foot). In November 2023, Blueberry announced that its Phase 2b clinical trial for BB2603 met its primary and secondary endpoints, showing significant effectiveness after just three months of treatment. The company is also developing treatments for other conditions such as acne and atopic dermatitis.
Blueberry Therapeutics has raised a total of $23.8 million over five funding rounds since its first round in 2015. Key investors include China Medical System, Medical Incubator Japan, Maven Capital Partners, and the GM&C Life Sciences Fund. The funding has supported the clinical development of its product pipeline, with plans to advance BB2603 into Phase 3 trials in the US and EU. According to a filing in April 2024, the company was reported as out of business due to bankruptcy and liquidation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 60.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Skin Care, Dermatology, Arts & Culture, Biotech and Pharma, DT and LS, rio ai health
- Technology
- Nanotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Blueberry Therapeutics is 210 monthly website visits, down 88.3% over the last three months. Blueberry Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Blueberry Therapeutics in the Macclesfield ecosystem
The Blueberry Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
SBRI Healthcare
Series A3 investors entered at this stage
GM&C Life Sciences Fund
Medical Incubator Japan- OIOmar Ibrahimi
Series B and later2 investors entered at this stage
China Medical System Holdings
Northern Powerhouse Investment Fund
Other known investors1 additional known investor
GC Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Blueberry Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Blueberry Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










